Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.32 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.32 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9459733 | 0.98 | KMT2A (0.35) | KMT2AALOX15SLC16A3SLC16A1MCTS1 | |
| Hydrochloric Acid SCHEMBL9460094 | 0.81 | CYP4F2 (0.33) | ALOX15CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL9459758 | 0.79 | CYP4F2 (0.37) | CYP4F2CYP4A11 | |
| Imidazole Acetic Acid SCHEMBL2787422 | 0.77 | GABRR1 (0.40) | — | |
| SCHEMBL18780360 | 0.77 | — | — | |
| SCHEMBL10348009 | 0.76 | PAM (0.46) | KMT2AALOX15 | |
| SCHEMBL26444929 | 0.75 | NPC1 (0.33) | — | |
| Imidazole Acetic Acid SCHEMBL637983 | 0.75 | — | — | |
| Imidazole Acetic Acid SCHEMBL9099789 | 0.75 | GABRR1 (0.41) | — | |
| Imidazole Acetic Acid SCHEMBL27340954 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192149-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192144-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192149-A1 | Imidazo Compounds | CYP19A1, CYP11B2, GPER1 | KMT2A 1116/4885ALOX15 4320/4885SLC16A3 2536/4885 |
| US-20090192144-A1 | Imidazo Compounds | REN, CYP11B2, CYP11B1 | KMT2A 3087/4885ALOX15 2419/4885SLC16A3 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.